Leor Perl

Leor Perl has extensive experience in the medical field, particularly in interventional cardiology. Leor currently serves as the Secretary for The Israeli Working Group on Interventional Cardiology at the Israel Heart Society. Prior to this, they held multiple roles at Beilinson - Rabin Medical Center, including Director of the Complex Cardiac Interventions Service, Chief Innovation Officer, and Interventional Cardiologist. Leor also served as the Medical Director at Vectorious Medical Technologies, where they contributed to the development of a novel approach to implantable long-term hemodynamic monitoring. Additionally, they worked as a Design Specialist at Edwards Lifesciences and as a CEC member at St. Jude Medical. Leor has also held positions as an Education Mentor at Biodesign By Rambam, Chairman of the Scientific Board at Powerful Medical, and as a Member at 8400 - The Health Network. Leor has previous experience as the Director of the Rabin Medical Center Innovation Laboratory and as a Researcher at Stanford University School of Medicine.

Leor Perl attended the Biodesign Innovation Fellowship program at Stanford University from 2016 to 2017. Prior to that, they studied Medicine at The Hebrew University of Jerusalem from 1999 to 2006, earning an MD degree. In 1998, they also spent a year at UC Santa Barbara, although specific details about their degree or field of study during that time are unavailable.

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Vectorious Medical Technologies

1 followers

Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy.The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration.Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.


Headquarters

Tel Aviv, Israel

Employees

11-50

Links